Johnson & Johnson to Pay $2.2 Billion in Settlement Over Criminal and Civil Investigations

Prescription Medicine
National Journal
Add to Briefcase
Sophie Novack
Nov. 4, 2013, 7:11 a.m.

Health care gi­ant John­son & John­son and its sub­si­di­ar­ies will pay more than $2.2 bil­lion to re­solve crim­in­al and civil in­vest­ig­a­tions, the De­part­ment of Justice an­nounced Monday.

Al­leg­a­tions re­late to the pre­scrip­tion drugs Risper­dal, Natre­cor, and In­venga. They in­clude fraud­u­lent pro­mo­tion of drugs for uses not ap­proved by the Food and Drug Ad­min­is­tra­tion, and kick­backs to phys­i­cians and phar­macists.

The set­tle­ment in­cludes $1.72 bil­lion in civil set­tle­ments with the fed­er­al gov­ern­ment and states and $485 mil­lion in crim­in­al fines and for­feit­ure.

“The con­duct at is­sue in this case jeop­ard­ized the health and safety of pa­tients and dam­aged the pub­lic trust,” At­tor­ney Gen­er­al Eric Hold­er said.  “This mult­i­bil­lion-dol­lar res­ol­u­tion demon­strates the Justice De­part­ment’s firm com­mit­ment to pre­vent­ing and com­bat­ing all forms of health care fraud.  And it proves our de­term­in­a­tion to hold ac­count­able any cor­por­a­tion that breaks the law and en­riches its bot­tom line at the ex­pense of the Amer­ic­an people.”

The $2.2 bil­lion res­ol­u­tion is one of the biggest health care fraud set­tle­ments in Amer­ic­an his­tory. 


Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.